Dr. Kane’s focus is on clinical studies in Head and Neck, GI and Thyroid cancer research.
Publications
The role of folates in squamous cell carcinoma of the head and neck. Cancer Detection and Prevention 29: 46-53
Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, Part 1. Oncology 19:775-8, 783-4, 788 passim
Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res : 11(23):8418-24
Phase II Trial of Dexamethasone, Vitamin D and Carboplatin in Patients with Hormone Refractory Prostate Cancer. Cancer
Gefitinib in Advanced Squamous cell carcinoma of the head and neck. Clinical Oncology
Phase II Trial: The use of trastuzumab. In: The Treatment of Hormone Refractory Prostate. Cancer
The promise of stereotactic radiation in a new era of oncology
Chemoprevention of squamous cell carcinoma of the oral cavity. Otolaryngology Clinics of North America
Phase II Trial of Dexamethasone, 1,25-Dihydroxyvitamin D and Carboplatin in Patients With Hormone Refractory Prostate Cancer. Proc ASCO: 302a
Schefter TE. Kavanagh BD. Raben D. Kane M. Chen C. Stuhr K. Kelly K. Mitchell JD. Bunn PA. Gaspar LE. A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. [Journal Article] International Journal of Radiation Oncology, Biology, Physics. 66(4 Suppl):S120-7, 2006 Nov 15.
Brown KS. Kane MA. Chemoprevention of squamous cell carcinoma of the oral cavity. [Review] [82 refs] [Journal Article. Review] Otolaryngologic Clinics of North America. 39(2):349-63, 2006 Apr.
Flaig TW. Barqawi A. Miller G. Kane M. Zeng C. Crawford ED. Glode LM. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. [Clinical Trial, Phase II. Journal Article. Research Support, Non-U.S. Gov't] Cancer. 107(2):266-74, 2006 Jul 15
Schefter TE. Patel M. McCarter M. Kane M. Russ PD. Nash SR. Shah RJ. Mitchell JD. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, Part 2. [Review] [61 refs] [Journal Article. Review] Oncology (Huntington). 19(7):830, 835-6, 838 passim, 2005 Jun
Pervez H, Kane MA (2006) Chemotherapy-induced neutropenia. Federal Practitioner Supplement 23: 1-8.
55. Chen H, Raben D, et al. KRAS Mutation Analysis in Patients with Locally Advanced Pancreatic Cancer (LAPC) Treated with Gefitinib and Chemoradiation Therapy (CT-PCR) in Phase I Trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part II. Vol 24, No. 18S (June 20 Supplement), 2006: #4106.
53. Raben D, Chen C, Eckhardt GS, Kane M, Song J, Bemis L, Varella-Garcia, M, Brualdi L, Hu K, Quon H, and Dancey J. Maturing toxicity and outcomes of a phase I trial of concurrent daily gefitinib and radiation or chemo-radiation for patients with locally advanced squamous cell carcinoma of the head and neck. Proceedings of the 47th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Denver, CO, Oct 16-20, 2005, Int J Radiat Oncol Biol Phys., Supp. 60(1), Abstract # 2237.
T. E. Schefter, A. Ballonoff, M. McCarter, R. Nash, M. Kane, R. Shah, D. Raben, B. Kavanagh (2007)Phase II trial of preoperative capecitabine and accelerated intensity modulated radiotherapy in locally advanced rectal cancer. ASCO GI Symposium #395
CHRISTOPHER D. WILLEY, M.D., PH.D.,* BARBARA A. MURPHY, M.D.,†
JAMES L. NETTERVILLE, M.D.,‡ BRIAN B. BURKEY, M.D.,‡ YU SHYR, PH.D.,§
BASHAR SHAKHTOUR, B.S.,§ BONNIE KISH, R.N., DAVID RABEN, M.D.,¶ CHANGHU CHEN, M.D. (2007) A PHASE II MULTI-INSTITUTIONAL TRIAL OF CHEMORADIATION USING
WEEKLY DOCETAXEL AND ERYTHROPOIETIN FOR HIGH-RISK
POSTOPERATIVE HEAD AND NECK CANCER PATIENTS. Int. J. Radiation Oncology Biol. Phys., In press
JOHN I. SONG, M.D.,** MADELEINE A. KANE, M.D., PH.D.,†† AND ANTHONY J. CMELAK, M.D.*
CHRISTOPHER D. WILLEY, M.D., PH.D.,* BARBARA A. MURPHY, M.D.,†
JAMES L. NETTERVILLE, M.D.,‡ BRIAN B. BURKEY, M.D.,‡ YU SHYR, PH.D.,§
BASHAR SHAKHTOUR, B.S.,§ BONNIE KISH, R.N., DAVID RABEN, M.D.,¶ CHANGHU CHEN, M.D. JOHN I. SONG, M.D.,** MADELEINE A. KANE, M.D., PH.D.,†† AND ANTHONY J. CMELAK, M.D.*(2007) A PHASE II MULTI-INSTITUTIONAL TRIAL OF CHEMORADIATION USING
WEEKLY DOCETAXEL AND ERYTHROPOIETIN FOR HIGH-RISK
POSTOPERATIVE HEAD AND NECK CANCER PATIENTS. Int. J. Radiation Oncology Biol. Phys., In press
30. Ballonoff A, Kavanagh D, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter, TE. Preoperative capecitabine and accelerated intensity modulated radiotherapy in locally advanced rectal cancer: A phase II trial. Am J Clin Oncol 31(2), In press, 2008.
31. Chen C, Kane MA, Song J, Campana J, Raben A, Hu K, Harrison L, Quon H, Dancey J, Baron A, Said S, Eckhardt SG, Raben D. A phase I trial of gefitnib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol, in press, 2008.
32. Kilbourn K, Anderson D, Costenaro A, Martin K, Kane M. The association between decisional self-efficacy, distress and risk behavior in head and neck cancer patients. Submitted, 2008.
33. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib (AG-13736) is an active treatment for all histological subtypes of advanced thyroid cancer: Results from a Phase II Study. J Clin Oncol, in press, 2008.
Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C (2008) Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope: 118(4)635-9.
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau, KF, Cohen RB (2008) Axitinib is an active treatment for all histological subtypes of advanced thyroid cancer: Results from a Phase II Study. JCO 26(29):4708-13.
Ballonoff A, Raben D, Rusthoven KE, Kane MA, Song JI and Chen C (2008) Outcomes of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma with N3 Neck Nodes Treated with Chemoradiation. Laryngoscope: 118(6): 995-8.
Olsen C, Schefter TE, Kane MA, Leong S, McCarter M, Chen Y, Eckhardt SG, Stiegmann G, Mack PC, Chen H and Raben D (2008) Results of a Phase I Trial of 12 Patients with Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimension Conformal Radiation. Am J Clin Oncol: 31(5): 1-8.
Ballonoff A, Kavanagh D, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter, TE (2008) Preoperative Capecitabine and Accelerated Intensity Modulated Radiotherapy in Locally Advanced Rectal Cancer: Phase II Trial. Am J Clin Oncol: 31(3): 264-70.
37. Kilbourn K, Anderson D, Costenaro A, Martin K, Kane M. (2008) “The Association Between Decisional Self-Efficacy, Distress and Risk Behavior in Head and Neck Cancer Patients”
A phase Ι study of gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies.
ASCO 2010
Rexinoid therapy for poorly differentiated thyroid cancer: A pilot clinical phase II trial and correlation to retinoid and peroxisome-proliferator activated receptor gamma receptors expression.
Approach to the Thyroid Cancer Patient with Extracervical Metastases. JCEM
Complete response and extended survival with aggressive chemotherapy and radiotherapy including selective internal radiation in metastatic esophageal adenocarcinoma . JCO submitted
Phase I/II SBRT for lung metastases
JCO 27:1579, 2009
Phase I/II SBRT for liver metastases
JCO 27:1572, 2009
Kras as a marker for response to gefitinib, paclitaxel and radiation therapy in locally advanced pancreatic cancer: Phase I/II study
AJCO 32: 115, 2009
Owonikoko T, Kono S, Saba N, Chen Z, Arabnia A, Chen A, Grist W, Brandt S, Jacob S, Srivatsa S, Sharma J, Weber C, Kane M, Lorch J, Grzegorzewski K, Rogerio J, Ramalingam S, Shin D, Khuri F. A Multicener Phase II Study of Everolimus and Pasireotide (SOM230) LAR in Advanced Metastatic Throid Cancer. ASCO, June 2012
Locati L, Licitra L, Agate L, Ou S-H I, Boucher A, Jarzab B, Qin, SK, Kane MA, Wirth LJ, Kim S, Ingrosso A, Kancier C, Bycott P, Cohen EEW. Phase 2 Trial of Axitinib for Advanced Thyroid Cancer: Preliminary Activity Results. To be presented at EHNS meeting 2012.
Haugen B, Klopper J, Kane M. (2012) “Anaplastic Thyroid Cancer and Miscellaneous Tumors of the Thyroid”, Werner and Lugbar’s The Thyroid, 10th edition; L. Braverman and D. Cooper, eds.
Desai K, Kane MA (2012) “Chemotherapy for Sinonasal Cancers” In: Sinonasal Tumors, A Chiu, V ramakrishnan, and J Suh, eds.
Kristol Das and Madeleine Kane, Multidisciplinary Thyroid Cancer Clinic Review (2003-2012) Presented at UCCC summer Fellows Poster Session, August 2012
Locati, L, Kane, MA, Cohen, EE et al. (2014) Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments, Under review by Cancer.
Klopper, J...Kane, MA...Haugen, B (2015)
"A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer" Thyroid: In Press
Locati, L, Licitra L, Agate L, Ou S-H, Boucher A, Jarzab B, Qin S, Kane M, Wirth L, Chen C, Kim S, Ingrosso A, Kancler C, Bycott P, Cohen E. (2014) Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic / Pharmacodynamic and Quality-of-Life Assessments. (UBC Envision Group) Cancer. Epub May 20, 2014,
Elizabeth R Kessler1,2, S Gail Eckhardt1,2, Todd M Pitts1,2, Erica L Bradshaw-Pierce2,3, Cindy L O'byrant4, Wells A Messersmith1,2, Sujatha Nallapreddy, Colin Weekes1,2, Jennifer Spratlin5, Christopher H Lieu1,2, Madeleine A Kane1,2, Sarah Eppers2, Elizabeth Freas2, Stephen Leong1,2 (2015) Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Investigational New Drugs: In preparation
S. Lindsey Davis, S. Gail Eckhardt, Jennifer R. Diamond, Wells A. Messersmith, Avind Dasari, Colin D. Weekes, Christopher H. Lieu, Madeleine Kane, Todd M. Pitts, Stephen Leong (2018) A phase 1, dose-escalation study of linsitinib (OSI-906), a small-molecule dual IGF-1R/insulin receptor kinase inhibitor, in combination with irinotecan in patients with advanced cancer, The Oncologist, under review
Sana D Karam, Dan Bowles*, Alicia M DeLouize, Madeleine Kane, Ayman Oweida, Tim Waxweiler, Dara L Aisner,, Hilary Somerset, Kurtis D Davies, Patrick Blatchford, Krishna Reddy, Aik Choo Tan, Antonio Jimeno, Xiao Jing Wang, and David Raben (2018)
Final Report of a Phase I Trial of Olaparib, an Oral Bioavailable PARP Inhibitor with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Accepted Clin Cancer Res
Keith C. Bible,1 Michael E. Menefee,2 Chia-Chia Lin,3 Michael J. Millward,4 William E. Maples,2 Boon Cher Goh,5 Nina J Karlin,6 Madeleine A. Kane,7 Douglas R. Adkins,8 Julian R. Molina,1 Ross C Donehower 9 Wan Tec Lim,5 Patrick J. Flynn,10 Ronald L Richardson,1 Anne M. Traynor,11 Joseph Rubin,1 Patricia M. LoRusso,12 Robert C. Smallridge,2 Jill K. Burton,1 Vera J. Suman,1 Aditi Kumar,1 Jessie S. Voss;1 Kandalaria M. Rumilla,1 Benjamin R. Kipp,1 Ashish V. Chintakuntlawar,1 Pamela Harris,13 Charles Erlichman1 and the Mayo Phase 2 Consortium. (2018)A Phase 2 International Study of Pazopanib in Progressive Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer: Supplemental (Confirmation) Cohort of MC057H Accepted by Thyroid.